NPS Pharma (NPSP) Submits CMC of NDA for GATTEX to U.S. FDA

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP), has submitted the chemistry, manufacturing and controls (CMC) section of its new drug application (NDA) for GATTEX (teduglutide) to the U.S. Food and Drug Administration (FDA).

GATTEX is a novel, recombinant analog of human glucagon-like peptide 2 that the company is developing for the treatment of adults with short bowel syndrome or SBS.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sky Quarry names Heidi Bowman as CFO
• Scholar Rock updates apitegromab regulatory status in U.S., Europe, Japan
• Robo.ai names Hao Wang of Changer.ae to its board of directors